이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

연구용 천연두 약물의 1상 시험

2026년 9월 9일 업데이트: SIGA Technologies

정상 건강한 지원자에서 항-오르토폭스바이러스 화합물 ST-246®의 형태 I 대 형태 V 캡슐의 단일 경구 투여량의 약동학에 대한 I상 무작위, 이중맹검, 교차, 탐색적 연구

The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

연구 개요

상세 설명

This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.

Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.

연구 유형

중재적

등록 (실제)

12

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Florida
      • Orlando, Florida, 미국, 32809
        • Orlando Clinical Research Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. 18 to 50 years
  2. Available for clinical follow-up duration of study.
  3. Able/willing to give written consent.
  4. Good general health; no clinically significant medical history.
  5. Refrain from taking any medications from screening through 72 hours after last dose.
  6. Adequate venous access.
  7. PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
  8. Meet Lab Criteria within 28 days prior to receipt of drug.
  9. Negative pregnancy test
  10. Non smokers
  11. No alcohol or caffeine
  12. Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study

Exclusion Criteria:

  1. Marked baseline prolongation of QT/corrected QT interval (QTc) interval (

  2. History of additional risk factors for Torsade de Pointes

  3. Clinically significant abnormal ECG

  4. Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval

  5. Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.

  6. History of any clinically significant conditions including:

    • Asthma
    • Diabetes mellitus
    • History of thyroidectomy or thyroid disease
    • Serious angioedema episodes
    • Head trauma resulting in a diagnosis of TBI other than concussion
    • Seizure or history of seizure
    • Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
    • Malignancy
  7. Family history of idiopathic seizures

  8. History or presence of neutropenia or other blood dyscrasia

  9. Known Hepatitis B or Hepatitis C infection

  10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.

  11. Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.

  12. Known clinically significant chronic viral infection (or current clinically significant viral infection

  13. History of frequent or severe headaches or migraines

  14. Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection

  15. Woman who is pregnant or is breast-feeding or planning to become pregnant

  16. On any concomitant medications

  17. History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.

  18. Inability to swallow medication

  19. Body Mass Index above 35 or below 18,

  20. Current drug abuse or alcohol abuse.

  21. Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice

  22. Clinically significant lactose intolerance

  23. Received experimental drug within 30 days

  24. Vaccination within 30 days

  25. Total of more than 350 milliliters (mL) of blood drawn in 2 months

  26. Treatment with any immunosuppressant or immunomodulatory medication in 3 months

  27. Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol

  28. History or diagnosis that would affect absorption of study medication

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Group ST-246 Form I (followed by Form V)

Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.

First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

다른 이름들:
  • 테코비리마트

Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.

다른 이름들:
  • 테코비리마트
활성 비교기: Group ST-246 Form V (followed by Form I)

Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.

First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

다른 이름들:
  • 테코비리마트

Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.

다른 이름들:
  • 테코비리마트

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles.

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL).

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL).

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax)

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
기간: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles.

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
기간: 4 weeks

Evaluated safety parameters included:

  1. physical examination/vital signs
  2. electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett)
  3. laboratory safety tests (hematology, chemistry, urinalysis)
  4. adverse events For a), b) and c), summary statistics (mean,SD, median, minm, maxm)for values, and changes from baseline(Day 1 pre-dose) to each timepoint, were measured and compared to laboratory normal reference ranges. Values for a)- d) were assigned grades according to DAIDS AE Grading Table. Any Grade of 3 or higher was considered severe and significant.
4 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Thomas C Marbury, MD, Orlando Clinical Research Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2008년 8월 1일

기본 완료 (실제)

2008년 10월 1일

연구 완료 (실제)

2008년 10월 1일

연구 등록 날짜

최초 제출

2008년 8월 1일

QC 기준을 충족하는 최초 제출

2008년 8월 5일

처음 게시됨 (추정된)

2008년 8월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 9일

마지막으로 확인됨

2010년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • SIGA-246-005
  • HHSN266200600014C (기타 보조금/기금 번호: NIAID)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다